WTO COVID-19 waiver: does the new draft move the talks forward?

A closer examination—paragraph by paragraph—of the re-draft shows how little has changed and how much may still lie ahead

By Peter Ungphakorn
POSTED MAY 25, 2021 | UPDATED JULY 27, 2021

The long-awaited revised proposal related to the COVID-19 pandemic, to waive obligations on intellectual property protection, was finally circulated to members of the World Trade Organization (WTO) on May 25.

This will allow the first negotiations to proceed in the WTO’s intellectual property council since the US swung behind the idea of a waiver, if not necessarily in the form proposed. (The council’s official name is the TRIPS Council — for “trade-related aspects of intellectual property rights”.)

A closer examination of the contents shows that a lot may still have to be negotiated. In other words, this is not just about accepting or rejecting the waiver — to waive or not to waive. What is in the text and what is left out are all significant. We can expect some rough times ahead.

Continue reading “WTO COVID-19 waiver: does the new draft move the talks forward?”

One to watch: Bolivia’s bid to import a Canadian COVID-19 vaccine

Multiple tests: Will Canada respond? Is the WTO system too cumbersome? Is this a better route than waiving intellectual property rights?

By Peter Ungphakorn
POSTED MAY 12, 2021 | UPDATED MAY 12, 2021

News broke late yesterday (May 11, 2021) that a Canadian company, Biolyse Pharma, had agreed to supply Bolivia with 15 million doses of Johnson & Johnson’s Janssen vaccine for COVID-19, without the patent-owner’s permission.

But the deal cannot go ahead until the Canadian government issues a “compulsory licence” for Biolyse Pharma to make the vaccine in Canada and export it to Bolivia.

Although the objective is to get a cheaper version of the vaccine to a developing country — Bolivia — a lot of the focus will be on Canada, which now holds the key.

Continue reading “One to watch: Bolivia’s bid to import a Canadian COVID-19 vaccine”

The proposed COVID-19 intellectual property waiver: too soon to predict

Will the US prevail? What actually lies ahead? How long will it take? And if the waiver is agreed, what impact will it have?

By Peter Ungphakorn
POSTED MAY 7, 2021 | UPDATED JUNE 5, 2021

It’s tempting to conclude that the proposed waiver on World Trade Organization (WTO) intellectual property rules related to the COVID-19 pandemic will swiftly be agreed now that the US is supporting it.

It’s also tempting to assume that if the waiver is agreed, then intellectual property on vaccines and other COVID-19 products will be freely available and in use around the world.

Neither of those will necessarily happen, and almost certainly not quickly.

Continue reading “The proposed COVID-19 intellectual property waiver: too soon to predict”

The WTO’s deadlock over an intellectual property waiver for COVID-19

Questions and explanations about why the waiver is proposed, why it’s opposed and what it would mean

Update: In a remarkable turn-around on May 5, 2021, US Trade Representative Katherine Tai announced the US would support the waiver and negotiate based on a proposed text. The press release referred only to COVID-19 vaccines, not other products. Tai said:

This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures. The Administration believes strongly in intellectual property protection, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines. We will actively participate in text-based negotiations at the World Trade Organization (WTO) needed to make that happen. Those negotiations will take time given the consensus-based nature of the institution and the complexity of the issues involved.

“The Administration’s aim is to get as many safe and effective vaccines to as many people as fast as possible. As our vaccine supply for the American people is secured, the Administration will continue to ramp up its efforts — working with the private sector and all possible partners — to expand vaccine manufacturing and distribution. It will also work to increase the raw materials needed to produce those vaccines
.”

More:
• After the May 2021 revised draft: WTO COVID-19 waiver: does the new draft move the talks forward?
• After the US announcement: The proposed COVID-19 intellectual property waiver: too soon to predict

By Peter Ungphakorn
POSTED DECEMBER 17, 2020 | UPDATED AUGUST 4, 2021

A petition with almost a million signatures was delivered to the World Trade Organization on December 9, 2020, calling for the WTO “to urgently ensure access to lifesaving Covid-19 vaccines, treatments and equipment for everyone in the world”.

We can overlook the fact that the WTO has no power to “ensure” anything of the kind. What the petition aimed to do was to support a proposal to waive WTO intellectual property rules temporarily where related to the COVID-19 pandemic.

The delivery was timed for the discussion the following day when members met as the Council for Trade Related Aspects of Intellectual Property Rights (the TRIPS Council). Since then, the proposal has gone nowhere.

Continue reading “The WTO’s deadlock over an intellectual property waiver for COVID-19”